Liệu pháp cứu chữa bằng phác đồ chứa lenalidomide cho bệnh Castleman tái phát/chịu trị: báo cáo về ba trường hợp

Soumerai JD, Sohani AR, Abramson JS. Diagnosis and management of Castleman disease. Cancer Control 2014; 21(4): 266–278 Ye B, Gao SG, Li W, Yang LH, Zhao SH, Ma K, Zhu XL, Liu XY, Sun KL. A retrospective study of unicentric and multicentric Castleman’s disease: a report of 52 patients. Med Oncol 2010; 27 (4): 1171–1178 Bower M, Newsom-Davis T, Naresh K, Merchant S, Lee B, Gazzard B, Stebbing J, Nelson M. Clinical features and outcome in HIVassociated multicentric Castleman’s disease. J Clin Oncol 2011; 29 (18): 2481–2486 Gérard L, Bérezné A, Galicier L, Meignin V, Obadia M, De Castro N, Jacomet C, Verdon R, Madelaine-Chambrin I, Boulanger E, Chevret S, Agbalika F, Oksenhendler E. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB Trial. J Clin Oncol 2007; 25(22): 3350–3356 Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, Orkin C, Webb A, Fisher M, Nelson M, Gazzard B, Stebbing J, Kelleher P. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 2007; 147(12): 836–839 Hoffmann C, Schmid H, Müller M, Teutsch C, van Lunzen J, Esser S, Wolf T, Wyen C, Sabranski M, Horst HA, Reuter S, Vogel M, Jäger H, Bogner J, Arasteh K. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood 2011; 118(13): 3499–3503 Marcelin AG, Aaron L, Mateus C, Gyan E, Gorin I, Viard JP, Calvez V, Dupin N. Rituximab therapy for HIV-associated Castleman disease. Blood 2003; 102(8): 2786–2788 Marrache F, Larroche C, Mémain N, Bouchaud O, Robineau M, Hermine O, Lortholary O. Prolonged remission of HIV-associated multicentric Castelman’s disease with an anti-CD20 monoclonal antibody as primary therapy. AIDS 2003; 17(9): 1409–1410 Powles T, Stebbing J, Montoto S, Nelson M, Gazzard B, Orkin C, Webb A, Bower M. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. Blood 2007; 110(12): 4132–4133 Nicoli P, Familiari U, Bosa M, Allice T, Mete F, Morotti A, Cilloni D, Saglio G, Guerrasio A. HHV8-positive, HIV-negative multicentric Castleman’s disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma. Int J Hematol 2009; 90(3): 392–396 Law AB, Ryan G, Lade S, Prince HM. Development of Kaposi’s sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient. Int J Hematol 2010; 91(2): 347–348 Ide M, Kawachi Y, Izumi Y, Kasagi K, Ogino T. Long-term remission in HIV-negative patients with multicentric Castleman’s disease using rituximab. Eur J Haematol 2006; 76(2): 119–123 Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 2013; 19(13): 3659–3670 Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005; 106(8): 2627–2632 Nagao A, Nakazawa S, Hanabusa H. Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases. J Hematol Oncol 2014; 7(1): 10 Adam Z, Szturz P, Křen L, Krejčí M, Pour L, Svoboda T, Hanke I, Penka I, Koukalová R, Rehák Z, Cervinková I, Storková T, Král Z, Mayer J. PET-CT documented fast onset of treatment response to cyclophosphamide, thalidomide and dexamethasone in patients with multicentric Castlemans disease. Case description and treatment information overview. Vnitr Lek 2013; 59(4): 301–312 (in Czech) Zhao X, Shi R, Jin X, Zheng J. Diffuse hyperpigmented plaques as cutaneous manifestation of multicentric Castleman disease and treatment with thalidomide: report of three cases. J Am Acad Dermatol 2011; 65(2): 430–432 Ramasamy K, Gandhi S, Tenant-Flowers M, Ceesay M, Corderoy S, Marcus R, Schey S. Rituximab and thalidomide combination therapy for Castleman disease. Br J Haematol 2012; 158(3): 421–423 Ghosh N, Grunwald MR, Fasan O, Bhutani M. Expanding role of lenalidomide in hematologic malignancies. Cancer Manag Res 2015; 7: 105–119 Tomás JF, Giraldo P, Lecumberri R, Nistal S. POEMS syndrome with severe neurological damage clinically recovered with lenalidomide. Haematologica 2012; 97(2): 320–322 Szturz P, Adam Z, Chovancová J, Stehlíková O, Klabusay M, Rehák Z, Koukalová R, Krejčí M, Pour L, Zahradová L, Hájek R, Mayer J. Lenalidomide: a new treatment option for Castleman disease. Leuk Lymphoma 2012; 53(10): 2089–2091 Szturz P, Adam Z, Rehak Z, Koukalova R, Kren L, Moulis M, Krejcí M, Mayer J. Salvage lenalidomide in four rare oncological diseases. Tumori 2013; 99(5): e251–e256 Szturz P, Adam Z, Rehák Z, Koukalová R, Sprláková-Puková A, Michalka J, Smardová L, Volfová P, Lengerová M, Mayer J. Castleman disease: retrospective single-center study of therapeutic results in 10 patients. Klin Onkol 2013; 26(2): 124–134 (in Czech) Chu BF, Shana’ah A, Hofmeister CC, Benson DM, Sell M, Tucker J, Pichiorri F, Efebera YA. Long-term therapy with lenalidomide in a patient with POEMS syndrome. Eur J Case Rep Intern Med 2014; 1: 2014_000093 Dispenzieri A. POEMS syndrome: update on diagnosis, riskstratification, and management. Am J Hematol 2015; 90(10): 951–962 Dispenzieri A, Klein CJ, Mauermann ML. Lenalidomide therapy in a patient with POEMS syndrome. Blood 2007; 110(3): 1075–1076 Royer B, Merlusca L, Abraham J, Musset L, Haroche J, Choquet S, Leleu X, Sebban C, Decaux O, Galicier L, Roussel M, Recher C, Banos A, Guichard I, Brisseau JM, Godmer P, Hermine O, Deplanque G, Facon T, Asli B, Leblond V, Fermand JP, Marolleau JP, Jaccard A. Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients. Am J Hematol 2013; 88(3): 207–212 Zagouri F, Kastritis E, Gavriatopoulou M, Sergentanis TN, Psaltopoulou T, Terpos E, Dimopoulos MA. Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. Leuk Lymphoma 2014; 55(9): 2018–2023 Yuan ZG, Dun XY, Li YH, Hou J. Treatment of multicentric Castleman’s disease accompanying multiple myeloma with bortezomib: a case report. J Hematol Oncol 2009; 2(1): 19 Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol 2016; 9(1): 52 Gupta N, Goh YT, Min CK, Lee JH, Kim K, Wong RS, Chim CS, Hanley MJ, Yang H, Venkatakrishnan K, Hui AM, Esseltine DL, Chng WJ. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. J Hematol Oncol 2015; 8(1): 103 Zhou N, Huang CW, Huang C, Liao W. The characterization and management of Castleman’s disease. J Int Med Res 2012; 40(4): 1580–1588 Lin Q, Fang B, Huang H, Yu F, Chai X, Zhang Y, Zhou J, Xia Q, Li Y, Song Y. Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman’s disease. Blood Cancer J 2015; 5(3): e298